Research and Markets: 2007 - Forest Laboratories Successfully Complete the Acquisition of Cerexa.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c57246) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Forest Laboratories Prospects to 2011 to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Forest Laboratories and its subsidiaries develop, manufacture and market branded and generic forms of prescription and non-prescription pharmaceutical products, primarily in the US and Europe. Its major products include Namenda for the treatment of moderate-to-severe Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , Lexapro for depression and generalised anxiety disorder anxiety disorder n. Any of various psychiatric disorders in which anxiety is either the primary disturbance or is the result of confronting a feared situation or object. , Benicar for hypertension and Campral for the maintenance of abstinence from alcohol in patients who are abstinent at treatment initiation. Since Forest is not able to afford the cost and risk of discovering and developing its own novel molecules, its business model involves acquiring products from other companies, at any stage from conception to approval. On 11th January 2007, Forest successfully completed the acquisition of Cerexa, a privately-held biopharmaceutical company based in Alameda, CA, in a cash-for-stock transaction with a purchase price of US$493.6 million plus a potential US$100 million milestone payment. As a result of the acquisition, Forest has obtained worldwide development and marketing rights (excluding Japan) to two injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. antibiotics (ceftaroline and ME1036) and an option to a third. To enhance its early-stage pipeline, Forest has entered into a second new collaboration with Gedeon Richter which will focus on a group of novel compounds that target the group 1 metabotropic glutamate receptors (mGluR1/5). mGluR1/5 antagonists represent novel, potential agents for the treatment of anxiety, depression, pain and other CNS See Continuous net settlement. CNS See continuous net settlement (CNS). conditions. The companies intend to advance promising leads to clinical trials within the next two to three years. In addition, with the acquisition of Cerexa, Forest has acquired ME1036, a carbapenem antibiotic in preclinical development. Topics Covered Latest Results Executive Summary Therapeutic Area Focus R&D Pipeline Central Nervous System Cardiovascular Other Appendix 1 - Financial Performance Appendix 2 - Key Corporate Events Appendix 3 - Key Agreements Appendix 4 - Infrastructure Appendix 5 - Key Pharmaceutical Subsidiaries Appendix 6 - Product Index Index of Tables Index of Charts Companies Mentioned * Almirall Prodesfarma This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. SA * Aurigene Discovery Technologies Ltd * BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group Ltd * Cypress Bioscience Inc * Daiichi Sankyo * Gedeon Richter Ltd * Glenmark Pharmaceuticals Ltd * INO Ino (ī`nō), in Greek mythology, daughter of Cadmus. She was the wife of Athamas, to whom she bore Learchus and Melicertes. She plotted to kill her stepchildren, Phrixus and Helle, but their mother, Nephele, saved them with the help of a winged Therapeutics * Lundbeck * Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. * Merz Pharma Merz Pharmaceuticals (Merz Pharma GmbH & Co. KGaA), a member of Merz Pharma, is an international healthcare company specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. GmbH & Co KGaA * Mylan Laboratories Inc * PAION AG * Recordati * Procter & Gamble * Samaritan Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/reports/c57246 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion